MK-5172: Interim Phase II data

Interim data from both cohorts of a double-blind Phase II trial in 332 treatment-naïve patients with chronic HCV genotype 1 infection showed that 82.8-93% of patients receiving once-daily 100, 200, 400 or 800 mg MK-5172 plus standard

Read the full 375 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE